替卡格雷
医学
氯吡格雷
内科学
普拉格雷
优势比
经皮冠状动脉介入治疗
急性冠脉综合征
回顾性队列研究
阿司匹林
心肌梗塞
作者
Taciéli F. da Rosa,Vitória Segabinazzi Foletto,Marissa Bolson Serafin,Bruno Rafael de Paula,Laísa Nunes Franco,S Marion,Augusto D. da Mota,Rosmari Hörner
标识
DOI:10.1016/j.ijantimicag.2023.106753
摘要
Recent data indicate that ticagrelor, used in acute coronary syndromes (ACS), has antibacterial effects against Staphylococcus sp. and other effects that may help management of infection. The primary objective of this study was to evaluate the protective effect of ticagrelor in patients who have had an ACS event and the risk of developing Staphylococcus aureus bacteremia (SAB) compared to a propensity-matched cohort receiving clopidogrel.This study was a retrospective, nationwide analysis of all patients presenting to any percutaneous coronary intervention-performing Veterans Affairs Medical Center with an ACS episode and resultant prescription for clopidogrel or ticagrelor. The primary outcome was the comparative rate of SAB in patients receiving ticagrelor vs. clopidogrel.Analysis involved 24 456 patients on ticagrelor and 277 277 patients on clopidogrel. There was a statistically significant difference in the number of patients developing SAB between the propensity-matched groups (32 [0.13%] of 24 456 for ticagrelor vs. 71 [0.29%] of 24 456 for clopidogrel; odds ratio (OR), 0.43; 95% confidence interval (CI), 0.28—0.65; P<0.0001). Multivariate logistic regression showed that receipt of clopidogrel, comorbid dermatologic condition, comorbid hematologic condition, and baseline anemia were independently associated with the development of SAB.The study findings align with recent reports that ticagrelor may have a beneficial role in the prevention of SAB.
科研通智能强力驱动
Strongly Powered by AbleSci AI